Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2005

View Archived Issues

SU-11248 effective in malignant pleural effusion model

Mechanisms underlying CAT-354's efficacy in asthma

U-74500A helps protect against antipsychotic-induced tardive dyskinesia

In vivo evidence for BN-82451 efficacy in Parkinson's disease

Further data on the antiarthritic effects of abatacept

Dimethylfumarate as a therapy for MS

Shire: Q1 developments

Depomed and New River sign development and license agreement

Kosan studies KOS-1022 in advanced hematologic malignancies

Portola and Astellas collaborate in thrombosis and atherosclerosis

Phase II trial for FavId in Europe

OncoVEX(GM-CSF) cleared for phase II study in malignant melanoma

Aloxi gets first European launch in Ireland

AS-1404 studied for ovarian cancer in new phase II trial

European orphan drug designation for Oncophage in renal cell carcinoma

Virulizin granted orphan drug status in Europe

Phase IIb study of NP-50301 for dry eye syndrome completes enrollment

TorreyPines Therapeutics files IND for Alzheimer's drug NGX-267

FASgen secures funding for FAS-20013 in MDR-TB

PediaMed studies GI dysfunction in children with autism

"Rotaviruses", the latest addition to the Drug R&D Backgrounders series, now available

LBH-589 increases immunosuppression induced by FK-778 and everolimus

New data on the therapeutic benefits of belatacept in renal transplantation

Update on the efficacy of repinotan in acute stroke

Recent patents describe new antiinfective agents

New agents for asthma and other respiratory diseases reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...